๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP ยท Real-Time Price ยท USD
68.55
-0.58 (-0.84%)
At close: Nov 20, 2026, 4:00 PM EST
68.90
+0.35 (0.51%)
After-hours: Nov 20, 2026, 7:39 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Rare disease now contributes more than half of sales, with Cortrophin demand strong despite near-term specialty pharmacy bottlenecks. The proposed Egetis acquisition adds Emcitate, with $300M+ peak sales potential and year-one EPS dilution expected.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Hi, good morning. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having ANI Pharmaceuticals here. Nikhil and Stephen, welcome. Nikhil, I believe you have some slides that you want to go through, then we can kind of go into Q&A.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. Good morning, everybody, and thank you for joining us at the Jefferies Conference. Thank you, Dennis and the Jefferies team, for having us here. Here's our standard forward-looking statements. ANI is a high-growth biopharmaceutical organization that's leading our transformation, accelerating our transformation into a leading rare disease company.

Our rare disease business accounts for more than 50% of our sales with our lead asset, Purified Cortrophin Gel, which is a strong multi-year growth opportunity. We're going to do about $480 million to $500 million in sales with that asset, but it has continuous growth available with it. Then we've recently made an offer to acquire Egetis Therapeutics with a lead asset called Emcitate that I will tell you about, to expand the scope and scale of our rare disease business.

At ANI, we have what we believe is a virtuous cycle of growth, where we take EBITDA and cash flows from our high-performing generics business and reinvest it into our rare disease business to accelerate our transformation into rare disease. When you think of ANI in numbers, we'll cross about $1.1 billion in sales this year, and our EBITDA, adjusted non-GAAP EBITDA, is at $290 million-$300 million, showing $295 million.

ANI has a strong improvement track record of growth, both on the top line as well as on the bottom line. You can see that over the past five years, we've had about 37% growth compounded on the top line, then our profitability has increased substantially with a 51% growth on the bottom line. Rare disease has been the primary driver of our growth. It's a business we launched in 2022 with our lead asset, Cortrophin Gel.

Year one of launch, we did $42 million of sales. That asset, our guidance for this year is 10x that, more than 10x that, at about $480 million-$500 million. On a combined basis, the rare disease business will account for $560 million-$585 million, where our second asset, ILUVIEN, will do $80 million-$85 million in sales. In the third quarter, Cortrophin delivered $138.7 million in sales.

Cortrophin is an asset that is used across multiple indications. Our existing specialties are neurology, nephrology, rheumatology, ophthalmology, and pulmonology. Across these five indications, we continue to have growth. These are the indications we launched with, or three of them we launched with, then we added sales later on with the other two, ophthalmology and pulmonology.

We continue to see very strong demand across our existing specialties, and that demand momentum has continued into October, where we saw the highest number of new cases initiated in October, as well as from the gout expansion. For gout, we expanded our sales force by about 50% to detail into primary care and podiatrists, and that expansion has gone very well, and we've seen very strong demand that we will talk about soon.

ILUVIEN had a very strong growth quarter too, with $22.3 million. Importantly, we announced phase IV study results, the SYNCHRONICITY data, that we believe will help prescribers think about ILUVIEN and the treatment of chronic NIU-PS. When you look at a total company basis, our guidance for the year is $1.085 billion-$1.125 billion, which is a 23%-27% growth.

For Cortrophin, our guidance is $480 million-$500 million, which is 38%-44% growth. ILUVIEN is $80 million-$85 million, which is 7%-14% growth. The adjusted non-GAAP EBITDA is at 26%-31% of growth, which is $290 million-$300 million. Importantly, our balance sheet is very strong. We've generated more than $200 million of cash in the last nine months from operations, and we're sitting at $421 million as of September 30th, and 0.7 turns of net leverage as of September 30th.

Lastly, before we go to Q&A, we made an offer to acquire Egetis Therapeutics, a Sweden-based rare disease company. Their lead asset, Emcitate, is the only approved therapeutic for peripheral thyrotoxicosis associated with MCT8 deficiency, which is an ultra-rare X-linked, which means it impacts only males, disease. It's a debilitating condition.

Most importantly, it allows us to bring this therapeutic to patients. It's the only approved therapeutic for this disease, and it allows us to bring this therapeutic and continue on our purpose of serving patients, improving lives, because it addresses a patient population that has no other alternative, and it's really a very debilitating life condition that has morbidity associated with it too.

We are grateful for the opportunity to bring this therapeutic to patients, not just in the U.S., but also globally. It leverages our rare disease infrastructure expertise, and adds and expands the scope and scale of our rare disease business. It also adds a pipeline for us, because the same drug, Emcitate, is being considered for development for the treatment of RTH-beta, which the Egetis team had been working on. It also brings that clinical development capability to ANI.

It's a durable, high-growth asset. It has patent that goes until 2045. It has ODE exclusivity until 2033. What it does in aggregate, it diversifies our revenue base from rare disease and improves the long-term growth and profitability. Heading towards the end of this decade, we'll have substantial majority of our sales and improved profitability across our rare disease business. I think I've covered most of this, so maybe I'll just turn it over to Dennis for Q&A.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Yeah, sure. Thanks, Nikhil, for those comments. Maybe we can just start off with the acquisition. Talk a little bit about the rationale behind it. Why now? Why today? And how do you think about the opportunity in the U.S.?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah. For those less familiar, ANI does not, in rare disease, as we are looking to expand our scope and scale of our rare disease business, we do not have our own R&D, so we look for external assets. And when we were looking at what kind of assets to add, we wanted to either leverage our front end, which is our sales force, that, as I was mentioning earlier, goes into multiple indications, rheumatology, nephrology, neurology, pulmonology, and ophthalmology, or the backbone of the rare disease business, which is patient support, medical affairs, specialty pharmacy distribution, market access.

What the Egetis Therapeutics acquisition does is it leverages the backbone, our rare disease infrastructure and backbone, and allows us to bring this important therapeutic, first in class, to patients in need. It has all of the attributes that we were looking for as we have been scanning assets.

It is a first-in-class therapeutic. It is FDA approved. That was important. We did not want to take clinical risk or regulatory risk at the time. It is an asset with peak sales $300 million plus, which is in the range of what we were looking for. It allows us to use our balance sheet, but does not stress our balance sheet beyond.

Even after close of this deal, we will be at 2.7 turns of net leverage with a path to delevering. So, I think it plays an important role in expanding the scope and scale of our rare disease business. Also, last but not least, it is also a profitable, improves the profitability profile for our rare disease business too.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Sure. In the U.S., because this is an ultra-rare-

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

condition, can you just remind us how many patients are identified? This is approved, and once you guys get the business integrated, you are going to go out there and prioritize those patients.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. The Egetis team, again, a lot of respect for them and what they have. It is really impressive what this company has achieved and the team has achieved globally in terms of getting the drug approved, but also the progress that they made. They have got it approved both in Europe and the U.S.

In Europe, they have launched in Germany, and they have doubled the number of patients since last year of the number of patients that are treated with MCT8, which is tremendous. In the U.S., they have identified more than 100 patients that are genetically validated. So they have identified and genetically validated more than 100 patients. Of those 100 plus patients, 60 are already on the expanded access program.

Since the approval on September 28th, their first focus has been to get these patients shifted from EAP onto the approved drug and through the commercial approval process, as well as the remaining 40 plus patients, because 100 minus 60 plus patients, also onto therapy. So that has been their initial focus. They have put in place a number of different elements that are needed for a successful launch, which is they have got partnerships with AnovoRx on the specialty pharmacy front, which is much needed for an ultra-rare indication like MCT8 deficiency.

They have also partnered with diagnostics organizations for the genetic testing as well as for the T3 level testing using LC-MS. They have also built a very strong relationship with the caregiver and the foundation associated with MCT8 deficiency. All of these are important building blocks in increasing awareness of MCT8 deficiency and the fact that there is now an available FDA-approved therapeutic for this indication.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

How quickly can you convert the 60 EAP patients onto commercial drug? What are the steps that need to be taken to get them onto reimbursed drug?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. First of all, in terms of deal timing, we are on track to close this deal by the end of this year, early next year, right? Early Q1. Until then, obviously, the Egetis team will keep driving. In terms of the process, I think it's a typical rare disease process, which is, they fill out enrollment forms, then that's checked for reimbursement, and then ultimately the drug is dispensed.

They're going through that process for the first 60 patients right now. We will update you on the progress as we go, but they are making good progress on o ur best understanding is they're making good progress on getting the patients through the enrollment process and also the additional patients that are genetically validated, getting them onto therapy too.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Yeah. What about pricing? Because I believe it's weight-based and there is a little bit of variability there.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. The price is $74,000 per pack. You are correct that it is weight-based. Of course, the important thing is when in the FDA-approved label, there is no age restriction. This drug can really be used for patients of all ages. The median survival for patients on MCT8 deficiency is 35 years. There is a host of patients that can benefit from this.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Okay. Because when I think about 2027, right?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

You have 60 patients. My math gets, on pricing, maybe it is $1 million a year on list, right? Going into 2027, you would already be annualizing at, let us call it $60 million once those EAP patients convert to commercial drug, right? Then you have some more visibility into the other 40 patients, et cetera, right? Do you think that is a fair assumption for 2027? Secondly, how do you think about expanding beyond the 100 patients that you guys have identified?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. We are not giving 2027 guidance today.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Sure.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Nice try, Dennis.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Had to try.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah, I know. I know. That's why I said nice try. I think, in terms of expansion of the diagnosed patient population, there are several epidemiological studies that say that the number of patients in the U.S. are more than 1,000. When you look at rare disease analogs, when a therapeutic, first-in-class therapeutic is available for an ultra-rare indication, the number of patients and the awareness of the disease goes up.

The number of patients that are diagnosed keeps increasing. In terms of the building blocks, Egetis has put a number of those building blocks in place, right, in terms of partnering with the foundation to understand where the patients are, connecting with the KOLs, right? Also putting in place the tools, right? The genetic testing, the LC-MS testing for elevated T3 levels. They're also using AI to see if the patients can be identified.

There are multiple different ways, building blocks that Egetis already has in place to identify the new patients. Look, the important thing is they've done the hard work of getting this drug approved. It's the only approved therapeutic for this debilitating genetic condition. We will do our best to get this to as many patients as possible, as fast as possible. Yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

How are you thinking about, I guess, the shape of the revenue trajectory over the next few years for this disease, right? I'm just trying to think about would there be sort of a bolus in 2027, because the process of identifying and diagnosing some of these patients, it could take a little bit of time, right? Maybe clarify, how you think about that over the next few years.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah. I think you can look at other rare disease analogs to say that the time to peak sales is over a period of years. It does not happen, for ultra-rare indications, it does not happen in year one. It takes multiple years to get there. We've said that, at least our initial, what we've communicated is $300 million plus in peak sales. So, yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

What goes into that $300 million peak sales assumption? I guess it's still really early, but, is there an element of conservatism in that number?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah, look, the $300 million peak sales number is something that we've underwritten the deal case with, right? It is an outcome of the diligence. Earlier you asked me this question around deal timing, which I didn't actually cover. This is an asset we've been monitoring for a while, right? We, as part of our BD process, monitor a number of different assets that we believe will add, they will help expand the scope of our rare disease business.

So we've been monitoring Egetis and this asset, MCT8, for a period of time, had done a bunch of market research, et cetera. So when they got FDA approval, which was one of the key criteria for us, and the process became competitive, we were ready. So the deal timing was really driven by the FDA approval than anything else.

And then, as you would expect, we have done a ton of diligence, and that informs, obviously, independent market research, but also diligence through the process that informs the $300 million plus peak sales number.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Sure. Okay. Maybe let's switch over to Cortrophin.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Talk about the updates in Q3, and some of the specialty pharmacy dynamics that you guys have laid out.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. So in Cortrophin, for the full year, we expect to see 38%-44% growth to $480 million-$500 million. That growth will come from two areas, our existing specialties, where we said rheumatology, nephrology, neurology, ophthalmology, and pulmonology. These are existing specialties. We continue to see significant growth from these areas in terms of demand, as well as patient conversion.

In October, we saw a record number of new cases initiated, which is prescriptions. Then from our gout expansion. So we expanded our sales force by about 50%, and added 16 new reps to take acute gouty arthritis flares, or take Cortrophin for acute gouty arthritis flares, to primary care specialists and podiatrists. This is an indication that only we have. We are the only ACTH drug that has that indication that our competitor does not. And we have seen very strong demand in this area too.

We've had a 67% growth, both breadth and depth. We've had a 67% growth in the number of prescribers writing Cortrophin for acute gouty arthritis flares from this primary care podiatry population in Q3 versus Q2. 40% of our prescribers, so this is depth, have initiated two or more cases. When you put these both together, the number of cases for acute gouty arthritis flares from primary care and podiatry has doubled in Q3 versus Q2. So the demand is very strong.

When you combine the demand from both the existing specialties and the gout expansion, we've had an 85% growth in the volume of cases initiated in the last five months, which is June through October, versus the first five months, which is January through May.

That strong growth really is the underlying driver of Cortrophin growth and the strong multi-year growth opportunity, because the addressable market for Cortrophin across indications is much larger than either us or the competitor is addressing. We're able to get prescribers to understand the importance of ACTH and for the appropriate patients, with over 50% of our prescribers being naive to ACTH.

With that strong demand, in the near term, we've had a bottleneck at the specialty pharmacy, where essentially the 85% growth that I just talked about was much higher than what we had planned for. The specialty pharmacy, which is, there are three steps in the process from enrollment to a patient getting on drug. There's the intake, which is the prescriber filling out the enrollment form or prescription.

Then there's the reimbursement process, which is getting the patient approved to get the drug. Then third is the dispensing of the drug. The specialty pharmacy plays a role across these, and then obviously we have internal resources too. They were just got bottlenecked, as with such a spike in demand. So that led to an issue with revenue conversion, and that is why we modified the guidance to only be 38%-44% growth over last year.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Yeah. What is really important, that I'm hearing from you, is that demand is really good, right? You put into place a lot of these expansion-

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Correct

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Things, like at the beginning of the year. You are starting to see volume pick up that is much bigger than what you expected, and this specialty pharmacy dynamic is just temporary.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Correct.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Right.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah, this is unambiguous, right? The demand for Cortrophin is strong, and the topics that we are working through, the dynamics we are working through, are near-term topics. It is a question of when, not if, in terms of revenue conversion and getting patients on paid drug. Yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Sure. Given that, and given that momentum-

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

And some of the initiatives that you are putting in place to resolve that specialty pharmacy bottleneck, how are you thinking about 2027 and your approach to guidance, just in broad strokes?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Nice try number two.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Broad strokes. Broad strokes.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah. No, look, I think the Cortrophin multi-year growth story is anchored in the addressable market, right? The addressable market across indications in our slide deck is much larger than anything that either us or the competitor together are addressing. And the demand is further proof of that driver of growth. As we look to 2027, we believe that Cortrophin will continue on its multi-year growth trajectory. And we will obviously carry forward the lessons from 2026 into 2027 as we think about growing from $480 million to $500 million and beyond.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Sure. Okay. Maybe talk a little bit about some of your comments around the integration of Egetis and its impact to the P&L. Yeah.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. Steve, do you want to take that?

Stephen Carey
CFO, ANI Pharmaceuticals

Yeah, sure. Thanks, Nikhil. Yeah, so obviously the product is right in the early stages of the U.S. launch, so that will continue in 2027. We have said we expect the deal to be dilutive to total company EPS in year number one, and then, right, build from there towards that $300 million of peak revenues. In the meantime, right, the base business, all of the elements of Cortrophin, ILUVIEN, the generic business continue to be, we expect to be strong, and continue on a growth trajectory, and continue very strong cash flows as well for the company.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Okay. I think what is really important is if you exclude the Egetis acquisition, right, the base business, EBITDA should continue to grow year over year. That is kind of the message.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yes, absolutely.

Stephen Carey
CFO, ANI Pharmaceuticals

That is correct.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Right. Okay. Okay. In the last minute, just talk about the generics business, because I think that has been a really solid bright spot this year, right?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Remind us how do you plan to fund that growth?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

How to think about growth in 2027 in the generics business?

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Sure. Generics is the base or the legacy business of the company. It continues to be a high-performing business. We invest about high single digits percentage of generic sales into R&D, and that's really the fuel for growth for the generics business. We have a U.S.-based manufacturing footprint and strong operational execution. With putting all of that together, we've delivered north of 25% compounded growth over the last five years.

This year, even on the back of a very strong 2026, we started the year saying we would be modestly down, then we said flat, and in our latest guidance, we said that we would be higher, modestly higher versus last year. We've launched 16 new products. We have 138 different product families, so we're doing about $384 million of sales last year, and we'll grow above that this year.

We have a very strong diversified business, strong outperformance, and it plays a very important role in generating EBITDA and cash flows that we use to fuel our rare disease business. On a standalone basis, it's a high-performing generics business. Yeah.

Dennis Ding
Biotech and Specialty Pharma Analyst, Jefferies

Okay, perfect. I think that's all the time that we have today, but it's great seeing you, and I hope you have a great conference.

Nikhil Lalwani
President and CEO, ANI Pharmaceuticals

Yeah. Thank you, everybody, for your time.